{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 78,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/41",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "CD200R1 expression is mainly expressed on immune cells; CD200 (ligand) is broadly expressed on many cell types. An anti-CD200 monoclonal antibody, samalizumab (ALXN 6000) did not saturate cell surface CD200. 23ME'610 is expected to saturate CD200R1.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f24ee1d-c4ba-4809-b1a3-bc74fee6c04d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1 Journal for ImmunoTherapy of Cancer 2019;7:227",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf0a0c1d-f8ab-46ba-8b79-316f7be54e16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.535
      },
      "kind": "table",
      "text": "Comparison table showing Target distribution and Antibody affinity (KD) for CD200R1 vs CD200.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72d86220-1e7e-4ced-93af-c0e1c6a0b05f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.84,
        "x": 0.08,
        "y": 0.05
      },
      "kind": "title",
      "text": "Why Target the Receptor (CD200R1) Instead of the Ligand?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "531b086e-bb21-490a-8d33-0e4940e1044d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "50074dcf-1b04-4609-a8e2-f6e470ad850a",
      "evidence": "The slide presents a comparison table highlighting the differences between targeting CD200R1 and CD200.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 33,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "934e5ad9-c4e2-4bad-8ae5-f1cb9185ca0d",
      "evidence": "The presentation deck presents data and research findings on 23ME-00610, a novel immuno-oncology antibody targeting CD200R1",
      "position": 1,
      "objective": "Can 23andMe's immuno-oncology antibody targeting CD200R1 provide a quick win in cancer treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}